title: [The role of HLA antigens in predicting the active course of multiple myeloma].
abstract: OBJECTIVE
  Detection of associations between carrying some HLA-antigens class I in patients with multiple myeloma (MM) and activity of the malignant process.
  
  
  METHODS
  76 MM patients received polychemotherapy. Its efficacy was assessed after one, three, six and twelve courses by reduced blood and/or urine levels of monoclonal protein, signs of bone healing, reestablishment of normal number of plasma cells in the bone marrow. Identification of HLA-antigens was made in two-stage lymphocytotoxic complement-mediated test using the standard panel of the anti-HLA sera. Data on HLA-typing of 865 blood donors served control. The findings were statistically processed.
  
  
  RESULTS
  All the patients were divided into 3 groups: with indolent (n = 18), active (n = 25) and aggressive (n = 37) MM course. In patients with aggressive MM course high chi-square values were estimated for three HLA specificities: HLA-B13, HLA-B40, HLA-B5. Only HLA-B13 proved significant. No significant differences in carrying HLA-antigens were revealed for patients with active MM course.
  
  
  CONCLUSIONS
  The survival of MM patients depends on the degree of the malignant process activity. Patients with aggressive MM course significantly more frequently carry HLA-B13, therefore it can be considered a genetic marker of MM. Its detection can serve a criterion for determination of adequate polychemotherapy.
authors.forename: M I
authors.initials: MI
authors.lastname: Zaraĭskiĭ
authors.forename: E I
authors.initials: EI
authors.lastname: Podol'tseva
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016009:Chi-Square Distribution; D018450:Disease Progression; D005819:Genetic Markers / Q000276:immunology; D015234:HLA-A Antigens / Q000097:blood*; D015235:HLA-B Antigens / Q000097:blood*; D006650:Histocompatibility Testing / Q000706:statistics & numerical data; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D005819:Genetic Markers; D015234:HLA-A Antigens; D015235:HLA-B Antigens